Gilead numbers ‘uninspiring’

TheStreet's Adam Feuerstein rated Gilead Science's second quarter numbers "uninspiring," with strong top-line results and a disappointment in earnings. As one of the few profitable biotechs in the market, though, the analysts concluded that a record of strong results would likely entice investors willing to overlook any short-term weakness. Report

Suggested Articles

Levo Therapeutics’ lead program did not beat placebo in a phase 3 study of Prader-Willi syndrome, a genetic disorder that causes insatiable hunger.

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.